◎社内に機能サービス本部創設 バイオ医薬品のパレクセル

パレクセル・インターナショナル

2013/6/25 14:05

◎社内に機能サービス本部創設 バイオ医薬品のパレクセル

AsiaNet 53497

共同JBN 0757 (2013.6.25)

【ボストン2013年6月24日PRN=共同JBN】有力な世界的バイオ医薬品サービス会社であるパレクセル・インターナショナル(PAREXEL International Corporation、http://www.parexel.com;NASDAQ:PRXL)は24日、同社の臨床研究サービス(http://www.parexel.com/clinical-research-services)事業部門内にパレクセル機能サービス本部(PAREXEL Functional Services Unit)を創設したと発表した。

パレクセルは、臨床開発プロセスにおける開発プログラム全体ではなく、特定機能のアウトソーシングに関心がある顧客向けのソリューションを提供するためにこの部署を立ち上げた。新本部は特に臨床操作、データ管理、生物統計学、医療文書執筆を提供する。これらのサービスは内部委託/人材配置、全面機能の外部委託、さらに特別注文のソリューションを含むエンゲージメントモデルを通じて提供される。機能ソーシングは戦略的提携の基礎を形成、あるいは機能、プログラム双方の外部委託を含むハイブリッド提携モデルの一部になり得る。

パレクセルの社長兼最高執行責任者(COO)、マーク・A・ゴールドバーグ医学士は「顧客は自社の薬剤開発方針と一致するアウトソーシングモデルを選ぶ際、ますますフレキシビリティーを必要とするようになった。われわれは本部創出によって、世界の機能サービス市場で競争するため一段と積極的かつ集中的な方策をとっている。とりわけ重要なのは、われわれが全面的なプログラム・機能アウトソーシングの幅広い組み合わせを提供、あらゆる規模の顧客との関係を強化できるということだ」と語った。

新設の機能サービス本部で責任者を務めるディエゴ・グランシュピーゲル副社長(臨床研究サービス担当)は「バイオ製薬会社は現在、効率的で費用効果がある方法で安全かつ高品質の製品を生産するため、薬剤開発プロセスの合理化という課題を抱えている。パレクセルの科学的な専門知識の深さと広さは、世界規模の事業展開や低コスト立地と相まって、各契約に付加価値をもたらすさまざまな機能に活用される」と語った。

新本部には献身的な幹部チームと支援要員が配置され、既存のパレクセル事業全体から地球規模の人材と専門知識を最大限に活用できる。パレクセル機能サービス本部は、市場機会を利用して顧客ニーズ対応を進化させるため、パレクセルが創設したいくつかの事業本部のひとつである。

▽パレクセル・インターナショナル(PAREXEL International Corporation)について

パレクセル・インターナショナルは世界的大手バイオ医薬品会社として、広い領域で知識ベースの委託研究(http://www.parexel.com/clinical-research-services)、コンサルティング、医療コミュニケーション・サービスを世界の医薬品、バイオテクノロジー、医療機器業界に提供している。市場進出時間、ピーク・マーケット・ペネトレーションを促進するソリューションの提供にコミットしているパレクセルは、医薬品開発と規制コンサルティングから臨床薬理学、臨床試験管理、医療教育、償還に至る開発と商業化の連続体全体にわたって重要な専門知識を身につけている。パレクセルの子会社であるPerceptive Infomatics, Inc.は、医療画像を含む先進的な技術ソリューションを提供して臨床開発プロセスを容易にしている。米マサチューセッツ州ボストン近くに本社を置くパレクセルは、世界52カ国の78カ所で活動しており、従業員は約1万4400人。パレクセル・インターナショナルについての詳しい情報はhttp://www.parexel.comを参照。

PAREXELはPAREXEL International Corporationの登録商標、Perceptive InfomaticsはPerceptive Infomatics, Inc.の登録商標。ほかのすべての名称、マークはPAREXEL International Corporation、Perceptive Infomatics, Inc.あるいはそれぞれの所有者の登録商標または商標であり、ここに通告する。

▽問い合わせ先

Diana Martin, Vice President, Corporate Communications

PAREXEL International

Tel: +1 781-434-5516

Email: Diana.Martin@PAREXEL.com

Matthew Briggs

PAN Communications

Tel: +1 617-502-4300

Email: PAREXEL@pancomm.com

ソース:PAREXEL International

PAREXEL Launches New Functional Services Unit

PR53497

BOSTON, June 24, 2013 /PRN=KYODO JBN/ --

PAREXEL (http://www.parexel.com) International Corporation (NASDAQ: PRXL), a

leading global biopharmaceutical services provider, today announced the launch

of PAREXEL Functional Services within the Company's Clinical Research Services

(http://www.parexel.com/clinical-research-services ) business segment.

PAREXEL created the unit to provide solutions for customers interested in

outsourcing particular functions rather than full development programs in the

clinical development process. The new operating unit will provide clinical

operations, data management, biostatistics, and medical writing, among others.

These services may be offered through a range of engagement models including

insourcing/staffing, full functional outsourcing, as well as customized

solutions. Functional sourcing may form the basis of a strategic partnership or

may be part of a hybrid partnership model that includes both functional and

programmatic outsourcing.

"Clients increasingly need flexibility when choosing an outsourcing model that

aligns with their path to drug development," said Mark A. Goldberg, M.D.,

President and Chief Operating Officer, PAREXEL. "By creating this operating

unit, we are taking a more proactive and focused approach to compete in the

growing global Functional Services market. Of particular importance, we'll be

able to strengthen our relationships with clients of all sizes by providing a

broader mix of full programmatic and functional outsourcing."

"Biopharmaceutical companies are challenged today with streamlining the

drug-development process to deliver the safest, highest quality products in the

most efficient and cost-effective manner," said Diego Glancszpigel, Corporate

Vice President, Clinical Research Services and new head of the Functional

Service operating unit. "PAREXEL's depth and breadth of scientific expertise,

along with our extensive global reach and low-cost locations, will be leveraged

across functions to add value to each engagement."

The new operating unit will be staffed by a dedicated leadership team and

supporting resources, taking full advantage of global resources and expertise

from across PAREXEL's existing operations. PAREXEL Functional Services is one

of several operating units PAREXEL has created to capitalize on market

opportunities and evolving client needs.  

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical

services organization, providing a broad range of knowledge-based contract

research (http://www.parexel.com/clinical-research-services), consulting, and

medical communications services to the worldwide pharmaceutical, biotechnology

and medical device industries. Committed to providing solutions that expedite

time-to-market and peak-market penetration, PAREXEL has developed significant

expertise across the development and commercialization continuum, from drug

development and regulatory consulting to clinical pharmacology, clinical trials

management, medical education and reimbursement. Perceptive Informatics, Inc.,

a subsidiary of PAREXEL, provides advanced technology solutions, including

medical imaging, to facilitate the clinical development process. Headquartered

near Boston, Massachusetts, PAREXEL operates in 78 locations throughout 52

countries around the world, and has approximately 14,400 employees. For more

information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and

events. For this purpose, any statements contained herein that are not

statements of historical fact may be deemed forward-looking statements. Without

limiting the foregoing, the words "believes," "anticipates," "plans,"

"expects," "intends," "appears," "estimates," "projects," "will," "would,"

"could," "should,"  "targets," and similar expressions are also intended to

identify forward-looking statements. The forward-looking statements in this

release involve a number of risks and uncertainties. The Company's actual

future results may differ significantly from the results discussed in the

forward-looking statements contained in this release. Important factors that

might cause such a difference include, but are not limited to, risks associated

with: actual operating performance; actual expense savings and other operating

improvements resulting from recent and anticipated restructurings; the loss,

modification, or delay of contracts which would, among other things, adversely

impact the Company's recognition of revenue included in backlog; the Company's

dependence on certain industries and clients; the Company's ability to win new

business, manage growth and costs, and attract and retain employees; the

Company's ability to complete additional acquisitions and to integrate newly

acquired businesses or enter into new lines of business; the impact on the

Company's business of government regulation of the drug, medical device and

biotechnology industry; consolidation within the pharmaceutical industry and

competition within the biopharmaceutical services industry; the potential for

significant liability to clients and third parties; the potential adverse

impact of health care reform; and the effects of exchange rate fluctuations and

other international economic, political, and other risks. Such factors and

others are discussed more fully in the section entitled "Risk Factors" of the

Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31,

2013 as filed with the SEC on May 6, 2013, which "Risk Factors" discussion is

incorporated by reference in this press release. The Company specifically

disclaims any obligation to update these forward-looking statements in the

future. These forward-looking statements should not be relied upon as

representing the Company's estimates or views as of any date subsequent to the

date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and

Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other

names or marks may be registered trademarks or trademarks of PAREXEL

International Corporation, Perceptive Informatics, Inc. or their respective

owners and are hereby acknowledged.

Contacts:

Diana Martin, Vice President, Corporate Communications

PAREXEL International

Tel: +1 781-434-5516

Email: Diana.Martin@PAREXEL.com

Matthew Briggs

PAN Communications

Tel: +1 617-502-4300

Email: PAREXEL@pancomm.com

SOURCE PAREXEL International

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

ソーシャルメディアでも最新のリリース情報をいち早く配信中